Kiromic Biopharma (KRBPQ) AI Stock Analysis

• Market Cap: $265.00
• Dividend Yield: N/A
• Average Volume (3M): 3.09K
• Price to Earnings (P/E): ―
• Beta (1Y): -2.05
• Revenue Growth: N/A
• EPS Growth: -4.26%
• Country: US
• Employees: 44
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 2,653,479
• 10 Day Avg. Volume: 3,734
• 30 Day Avg. Volume: 3,091
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: 0.00
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 28 Underperform
• Price Target: ―
• Action: N/A Date: 04/22/25
• Date: Action: N/A 04/22/25

Kiromic Biopharma faces significant financial challenges with no revenue and increasing losses, leading to a low financial performance score. Technical indicators signal a strong bearish trend, further impacting the stock negatively. The lack of earnings results in a poor valuation score. Overall, the stock presents a high-risk investment with substantial financial and operational concerns.

Positive Factors

Innovative Technology Platforms

Kiromic Biopharma's focus on proprietary technology platforms in immuno-oncology positions it to potentially revolutionize cancer treatment, offering long-term competitive advantages in the biotechnology sector.

Focus on Immuno-Oncology

Kiromic's specialization in immuno-oncology taps into a growing sector with significant demand for innovative cancer therapies, potentially driving future revenue and market leadership.

Strategic Alliances

Partnerships with larger companies can enhance Kiromic's financial stability and market penetration, crucial for sustaining operations and achieving long-term growth in the competitive biotech industry.

Negative Factors

Increasing Losses

Rising losses reflect high R&D expenses without offsetting revenue, challenging Kiromic's financial sustainability and necessitating strategic pivots to achieve profitability.

Lack of Revenue

The absence of revenue is a critical concern, as it limits Kiromic's ability to sustain operations and invest in R&D, potentially hindering long-term growth and competitiveness.

Negative Equity

Negative equity suggests financial instability, posing risks to Kiromic's long-term viability and ability to fund its operations without significant restructuring or additional capital.

Kiromic Biopharma Business Overview & Revenue Model

Company Description

Kiromic BioPharma, Inc., an artificial intelligence driven allogeneic cell therapy company, engages in developing the multi-indication allogeneic T cell therapies that exploits the natural potency of the Gamma Delta T cell to target solid tumors. The company develops ALEXIS-ISO-1, an allogenic gamma delta CAR-T cell therapy product candidate targeting Isomesothelin; and ALEXIS-PRO-1, an allogeneic gamma delta chimeric T cell therapy product candidate targeting PD-L1. It has license agreements with CGA 369 Intellectual Holdings, Inc. and Longwood University, as well as a research and development collaboration agreement with Molipharma, S.R.L. The company also has strategic alliance agreement with Leon Office (H.K.) Ltd. The company was formerly known as Kiromic, Inc. and changed its name to Kiromic BioPharma, Inc. in December 2019. Kiromic BioPharma, Inc. was founded in 2006 and is headquartered in Houston, Texas.

How the Company Makes Money

Kiromic Biopharma makes money primarily through the development and commercialization of its immuno-oncology products. The company generates revenue by licensing its technology platforms and collaborating with pharmaceutical companies to develop new cancer therapies. Key revenue streams include milestone payments from partnerships, research funding, and eventually, product sales if their therapies receive regulatory approval. Significant factors contributing to its earnings include successful clinical trial results and strategic alliances with larger biotech or pharmaceutical companies, which can provide both financial support and expanded market reach.

Kiromic Biopharma Financial Statement Overview

Summary

Kiromic Biopharma is struggling financially, with no revenue, increasing losses, negative equity, and poor cash flow metrics. The company's reliance on financing to sustain operations poses significant risks. Immediate strategic pivots or funding solutions are essential to ensure long-term viability.

Income Statement

Kiromic Biopharma has not generated any revenue over the past years, and its net losses have been increasing. Operating losses are significant, reflecting high research and development expenses typical in biotech. The absence of revenue and growing losses are concerning for financial sustainability.

Balance Sheet

The company has a negative stockholders' equity, indicating liabilities exceed assets. This is a red flag for financial health. High debt levels relative to equity suggest potential solvency issues. The consistent negative equity ratio is a major risk factor.

Cash Flow

Cash flow from operations is consistently negative, indicating poor cash generation from core activities. Free cash flow is also negative, suggesting the company relies heavily on external financing for operations. Despite significant financing inflows, the sustainability of such cash flows is questionable.

Breakdown
Income Statement
Total Revenue
Gross Profit
EBITDA
Net Income
Balance Sheet
Total Assets
Cash, Cash Equivalents and Short-Term Investments
Total Debt
Total Liabilities
Stockholders Equity
Cash Flow
Free Cash Flow
Operating Cash Flow
Investing Cash Flow
Financing Cash Flow

Kiromic Biopharma Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.04
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KRBPQ, the sentiment is Negative. The current price of 0.04 is below the 20-day moving average (MA) of 0.04, above the 50-day MA of 0.04, and below the 200-day MA of 0.46, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 44.56 is Neutral, neither overbought nor oversold. The STOCH value of 71.43 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for KRBPQ.

Kiromic Biopharma Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SCNI	49 Neutral	$603.58K	-0.24	―	―	178.82%	-4121.10%
DRMA	47 Neutral	$4.14M	-0.76	-203.36%	―	―	90.53%
AZTR	42 Neutral	$4.58M	-0.12	-215.04%	―	-100.00%	93.82%
KRBPQ	28 Underperform	$265.00	>-0.01	―	―	―	-4.26%